中外医疗China&ForeignMedicalTreatment药物与临床药物与临床中外医疗China&ForeignMedicalTreatment2024NO.3吡非尼酮联合乙酰半胱氨酸治疗特发性肺间质纤维化的疗效评价刘贞祥，王军，崔晓靖寿光市中医医院肺病科，山东潍坊262700［摘要］目的探究吡非尼酮联合乙酰半胱氨酸治疗特发性肺间质纤维化的疗效。方法回顾性选取2018年1月—2023年1月寿光市中医医院100例特发性肺间质纤维化患者的临床资料，按照用药方案不同分为两组，每组50例。对照组实施吡非尼酮治疗，观察组实施吡非尼酮联合乙酰半胱氨酸治疗。比较两组患者治疗效果。结果观察组治疗有效率（96.00%）高于对照组的80.00%，差异有统计学意义（χ2=6.060，P<0.05）。观察组肺部功能指标水平明显高于对照组，差异有统计学意义（P<0.05）。观察组不良反应发生率低于对照组，差异有统计学意义（P<0.05）。观察组肺纤维化指标水平明显低于对照组，差异有统计学意义（P<0.05）。结论吡非尼酮、乙酰半胱氨酸联合的方法治疗特发性肺间质纤维化患者，可改善患者临床症状，显著提升治疗效果。［关键词］吡非尼酮；乙酰半胱氨酸；特发性；肺间质纤维化［中图分类号］R563［文献标识码］A［文章编号］1674-0742（2024）01(c)-0120-04EfficacyEvaluationofPirfenidoneCombinedwithAcetylcysteineintheTreatmentofIdiopathicPulmonaryInterstitialFibrosisLIUZhenxiang,WANGJun,CUIXiaojingDepartmentofPulmonaryDisease,ShouguangHospitalofTraditionalChineseMedicine,Weifang,ShandongProvince,262700China[Abstract]ObjectiveToexplorethetherapeuticeffectofpirfenidonecombinedwithacetylcysteineonidiopathicpul⁃monaryinterstitialfibrosis.MethodsClinicaldataof100patientswithidiopathicpulmonaryinterstitialfibrosisinShouguangHospitalofTraditionalChineseMedicinefromJanuary2018toJanuary2023wereretrospectivelyselectedanddividedintotwogroupsaccordingtodifferentmedicationregimens,with50casesineachgroup.Thecontrolgroupwastreatedwithpirfenidone,andtheobservationgroupwastreatedwithpirfenidonecombinedwithacetylcyste⁃ine.Thetherapeuticeffectofthetwogroupswascompared.ResultsTheeffectiverateoftreatmentinobservationgroup96.00%washigherthanthatincontrolgroup(80.00%),thedifferencewasstatisticallysignificant(χ2=6.060,P<0.05).Theleveloflungfunctionin...
